Matthew Smalley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew Smalley has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Hsian-Rong Tseng
California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology
6 shared publications - Yazhen Zhu
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA
6 shared publications - Na Sun
CAS Key Laboratory for Nano‐Bio Interface Suzhou Institute of Nano‐Tech and Nano‐Bionics Chinese Academy of Sciences Suzhou 215123 China
4 shared publications - Ryan Y. Zhang
California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, USA
4 shared publications - Dongping Qi
Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, USA
3 shared publications - Jiantong Dong
Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
3 shared publications
Latest Publications
- Open Access
- 23 October 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (43) , eabb7107
Supramolecular nanosubstrate–mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies
CRISPR-Cas9 knockin of the HBB gene paves the way for a general therapeutic solution for treating hemoglobinopathies.
- 23 October 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (43) , eabb7107
Open AccessSupramolecular nanosubstrate–mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies
CRISPR-Cas9 knockin of the HBB gene paves the way for a general therapeutic solution for treating hemoglobinopathies.
- 13 September 2020
- Published by Wiley in Advanced Functional Materials
- Vol. 30 (49) , 2003237
Coupling Nanostructured Microchips with Covalent Chemistry Enables Purification of Sarcoma‐Derived Extracellular Vesicles for Downstream Functional Studies
Tumor‐derived extracellular vesicles (EVs) play essential roles in intercellular communication during tumor growth and metastatic evolution. Currently, little is known about the possible roles of tumor‐derived EVs in sarcoma because the lack of specific surface markers makes it technically challenging to purify sarcoma‐derived EVs. In this study, a specific purification system is developed for Ewing sarcoma (ES)‐derived EVs by coupling covalent chemistry‐mediated EV capture/release within a nanostructure‐embedded microchip. The purification platform—ES‐EV Click Chip—takes advantage of specific anti‐LINGO‐1 recognition and sensitive click chemistry‐mediated EV capture, followed by disulfide cleavage‐driven EV release. Since the device is capable of specific and efficient purification of intact ES EVs with high purity, ES‐EV Click Chip is ideal for conducting downstream functional studies of ES EVs. Absolute quantification of the molecular hallmark of ES (i.e., EWS rearrangements) using reverse transcription Droplet Digital PCR enables specific quantification of ES EVs. The purified ES EVs can be internalized by recipient cells and transfer their mRNA cargoes, exhibiting their biological intactness and potential role as biological shuttles in intercellular communication.
- 13 September 2020
- Published by Wiley in Advanced Functional Materials
- Vol. 30 (49) , 2003237
Coupling Nanostructured Microchips with Covalent Chemistry Enables Purification of Sarcoma‐Derived Extracellular Vesicles for Downstream Functional Studies
Tumor‐derived extracellular vesicles (EVs) play essential roles in intercellular communication during tumor growth and metastatic evolution. Currently, little is known about the possible roles of tumor‐derived EVs in sarcoma because the lack of specific surface markers makes it technically challenging to purify sarcoma‐derived EVs. In this study, a specific purification system is developed for Ewing sarcoma (ES)‐derived EVs by coupling covalent chemistry‐mediated EV capture/release within a nanostructure‐embedded microchip. The purification platform—ES‐EV Click Chip—takes advantage of specific anti‐LINGO‐1 recognition and sensitive click chemistry‐mediated EV capture, followed by disulfide cleavage‐driven EV release. Since the device is capable of specific and efficient purification of intact ES EVs with high purity, ES‐EV Click Chip is ideal for conducting downstream functional studies of ES EVs. Absolute quantification of the molecular hallmark of ES (i.e., EWS rearrangements) using reverse transcription Droplet Digital PCR enables specific quantification of ES EVs. The purified ES EVs can be internalized by recipient cells and transfer their mRNA cargoes, exhibiting their biological intactness and potential role as biological shuttles in intercellular communication.
- Open Access
- 7 September 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-12
Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
We report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific extracellular vesicle (EV) purification system for early detection of HCC by performing digital scoring on the purified EVs. Earlier detection of HCC creates more opportunities for curative therapeutic interventions. EVs are present in circulation at relatively early stages of disease, providing potential opportunities for HCC early detection. We develop an HCC EV purification system (i.e., EV Click Chips) by synergistically integrating covalent chemistry-mediated EV capture/release, multimarker antibody cocktails, nanostructured substrates, and microfluidic chaotic mixers. We then explore the translational potential of EV Click Chips using 158 plasma samples of HCC patients and control cohorts. The purified HCC EVs are subjected to reverse-transcription droplet digital PCR for quantification of 10 HCC-specific mRNA markers and computation of digital scoring. The HCC EV-derived molecular signatures exhibit great potential for noninvasive early detection of HCC from at-risk cirrhotic patients with an area under receiver operator characteristic curve of 0.93 (95% CI, 0.86 to 1.00; sensitivity = 94.4%, specificity = 88.5%).
- 7 September 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-12
Open AccessPurification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
We report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific extracellular vesicle (EV) purification system for early detection of HCC by performing digital scoring on the purified EVs. Earlier detection of HCC creates more opportunities for curative therapeutic interventions. EVs are present in circulation at relatively early stages of disease, providing potential opportunities for HCC early detection. We develop an HCC EV purification system (i.e., EV Click Chips) by synergistically integrating covalent chemistry-mediated EV capture/release, multimarker antibody cocktails, nanostructured substrates, and microfluidic chaotic mixers. We then explore the translational potential of EV Click Chips using 158 plasma samples of HCC patients and control cohorts. The purified HCC EVs are subjected to reverse-transcription droplet digital PCR for quantification of 10 HCC-specific mRNA markers and computation of digital scoring. The HCC EV-derived molecular signatures exhibit great potential for noninvasive early detection of HCC from at-risk cirrhotic patients with an area under receiver operator characteristic curve of 0.93 (95% CI, 0.86 to 1.00; sensitivity = 94.4%, specificity = 88.5%).
- Open Access
- 2 July 2020
- Published by Springer Nature in npj Precision Oncology
- Vol. 4 (1) , 1-9
Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells
Somatic copy number alterations (SCNAs) are important genetic drivers of many cancers. We investigated the feasibility of obtaining SCNA profiles from circulating tumor cells (CTCs) as a molecular liquid biopsy for hepatocellular carcinoma (HCC). CTCs from ten HCC patients underwent SCNA profiling. The Cancer Genome Atlas (TCGA) SCNA data were used to develop a cancer origin classification model, which was then evaluated for classifying 44 CTCs from multiple cancer types. Sequencing of 18 CTC samples (median: 4 CTCs/sample) from 10 HCC patients using a low-resolution whole-genome sequencing strategy (median: 0.88 million reads/sample) revealed frequent SCNAs in previously reported HCC regions such as 8q amplifications and 17p deletions. SCNA profiling revealed that CTCs share a median of 80% concordance with the primary tumor. CTCs had SCNAs not seen in the primary tumor, some with prognostic implications. Using a SCNA profiling model, the tissue of origin was correctly identified for 32/44 (73%) CTCs from 12/16 (75%) patients with different cancer types.
- 2 July 2020
- Published by Springer Nature in npj Precision Oncology
- Vol. 4 (1) , 1-9
Open AccessSomatic copy number profiling from hepatocellular carcinoma circulating tumor cells
Somatic copy number alterations (SCNAs) are important genetic drivers of many cancers. We investigated the feasibility of obtaining SCNA profiles from circulating tumor cells (CTCs) as a molecular liquid biopsy for hepatocellular carcinoma (HCC). CTCs from ten HCC patients underwent SCNA profiling. The Cancer Genome Atlas (TCGA) SCNA data were used to develop a cancer origin classification model, which was then evaluated for classifying 44 CTCs from multiple cancer types. Sequencing of 18 CTC samples (median: 4 CTCs/sample) from 10 HCC patients using a low-resolution whole-genome sequencing strategy (median: 0.88 million reads/sample) revealed frequent SCNAs in previously reported HCC regions such as 8q amplifications and 17p deletions. SCNA profiling revealed that CTCs share a median of 80% concordance with the primary tumor. CTCs had SCNAs not seen in the primary tumor, some with prognostic implications. Using a SCNA profiling model, the tissue of origin was correctly identified for 32/44 (73%) CTCs from 12/16 (75%) patients with different cancer types.
- 30 September 2019
- Published by Wiley in Advanced Materials
- Vol. 32 (1) , e1903663
Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications
Circulating rare cells in the blood are of great significance for both materials research and clinical applications. For example, circulating tumor cells (CTCs) have been demonstrated as useful biomarkers for “liquid biopsy” of the tumor. Circulating fetal nucleated cells (CFNCs) have shown potential in noninvasive prenatal diagnostics. However, it is technically challenging to detect and isolate circulating rare cells due to their extremely low abundance compared to hematologic cells. Nanostructured substrates offer a unique solution to address these challenges by providing local topographic interactions to strengthen cell adhesion and large surface areas for grafting capture agents, resulting in improved cell capture efficiency, purity, sensitivity, and reproducibility. In addition, rare‐cell retrieval strategies, including stimulus‐responsiveness and additive reagent‐triggered release on different nanostructured substrates, allow for on‐demand retrieval of the captured CTCs/CFNCs with high cell viability and molecular integrity. Several nanostructured substrate‐enabled CTC/CFNC assays are observed maturing from enumeration and subclassification to molecular analyses. These can one day become powerful tools in disease diagnosis, prognostic prediction, and dynamic monitoring of therapeutic response—paving the way for personalized medical care.
- 30 September 2019
- Published by Wiley in Advanced Materials
- Vol. 32 (1) , e1903663
Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications
Circulating rare cells in the blood are of great significance for both materials research and clinical applications. For example, circulating tumor cells (CTCs) have been demonstrated as useful biomarkers for “liquid biopsy” of the tumor. Circulating fetal nucleated cells (CFNCs) have shown potential in noninvasive prenatal diagnostics. However, it is technically challenging to detect and isolate circulating rare cells due to their extremely low abundance compared to hematologic cells. Nanostructured substrates offer a unique solution to address these challenges by providing local topographic interactions to strengthen cell adhesion and large surface areas for grafting capture agents, resulting in improved cell capture efficiency, purity, sensitivity, and reproducibility. In addition, rare‐cell retrieval strategies, including stimulus‐responsiveness and additive reagent‐triggered release on different nanostructured substrates, allow for on‐demand retrieval of the captured CTCs/CFNCs with high cell viability and molecular integrity. Several nanostructured substrate‐enabled CTC/CFNC assays are observed maturing from enumeration and subclassification to molecular analyses. These can one day become powerful tools in disease diagnosis, prognostic prediction, and dynamic monitoring of therapeutic response—paving the way for personalized medical care.
- 20 March 2019
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (15) , 13973-13983
Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer
Tumor-derived extracellular vesicles (EVs) present in bodily fluids are emerging liquid biopsy markers for non-invasive cancer diagnosis and treatment monitoring. Because the majority of EVs in circulation are not of tumor origin, it is critical to develop new platforms capable of enriching tumor-derived EVs from the blood. Herein, we introduce a biostructure-inspired NanoVilli Chip, capable of highly efficient and reproducible immunoaffinity capture of tumor-derived EVs from blood plasma samples. Anti-EpCAM-grafted silicon nanowire arrays were engineered to mimic the distinctive structures of intestinal microvilli, dramatically increasing surface area and enhancing tumor-derived EV capture. RNA in the captured EVs can be recovered for downstream molecular analyses by reverse transcription Droplet Digital PCR. We demonstrate that this assay can be applied to monitor the dynamic changes of ROS1 rearrangements and epidermal growth factor receptor T790M mutations that predict treatment responses and disease progression in non-small cell lung cancer patients.
- 20 March 2019
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (15) , 13973-13983
Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer
Tumor-derived extracellular vesicles (EVs) present in bodily fluids are emerging liquid biopsy markers for non-invasive cancer diagnosis and treatment monitoring. Because the majority of EVs in circulation are not of tumor origin, it is critical to develop new platforms capable of enriching tumor-derived EVs from the blood. Herein, we introduce a biostructure-inspired NanoVilli Chip, capable of highly efficient and reproducible immunoaffinity capture of tumor-derived EVs from blood plasma samples. Anti-EpCAM-grafted silicon nanowire arrays were engineered to mimic the distinctive structures of intestinal microvilli, dramatically increasing surface area and enhancing tumor-derived EV capture. RNA in the captured EVs can be recovered for downstream molecular analyses by reverse transcription Droplet Digital PCR. We demonstrate that this assay can be applied to monitor the dynamic changes of ROS1 rearrangements and epidermal growth factor receptor T790M mutations that predict treatment responses and disease progression in non-small cell lung cancer patients.